search for




 

Clinical application of a new hemostatic material using mussel-inspired catecholamine hemostat: A pilot study
Ann Hepatobiliary Pancreat Surg
Published online November 29, 2021;  https://doi.org/10.14701/ahbps.21-077
Copyright © 2021 The Korean Association of Hepato-Biliary-Pancreatic Surgery.

Young-Mok Park1, Hyung-Il Seo1, Jae-Hoon Kim2, Sung Pil Yoon3, Haeshin Lee4, Moon Sue Lee5

1Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea,
2Department of Trauma Surgery and Surgical Critical Care, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea,
3Department of Surgery, Gang-an Hospital, Busan, Korea,
4Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea,
5InnoTherapy Inc., Seoul, Korea
Correspondence to: Hyung-Il Seo
Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea
Tel: +82-51-240-7238, Fax: +82-51-247-1365, E-mail: seohi71@hanmail.net
ORCID: https://orcid.org/0000-0002-4132-7662
Received May 31, 2021; Revised August 2, 2021; Accepted August 16, 2021.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Backgrounds/Aims: This study aimed to evaluate clinical application of InnoSEAL Plus (a mussel-inspired catecholamine hemostat) as a new hemostatic material for humans.
Methods: Patients treated with topical hemostatic patches after liver resection were enrolled. They were divided into an experimental group (InnoSEAL Plus group) and two control groups (TachoSil® group and Surgicel Fibrillar® group) for efficacy evaluation.
Results: A total of 15 patients were enrolled. Each group had five patients. The 3-minute hemostasis success rate was 80.0% (4/5 patients) in the InnoSEAL Plus group, 80.0% (4/5 patients) in the TachoSil® group, and 40.0% (2/5 patients) in the Surgicel Fibrillar® group, showing no significant difference in the success rate among these groups (p > 0.05). All three groups exhibited 100% success rate for 10-minute hemostasis. Both InnoSEAL Plus and TachoSil® groups had one patient developing adverse events, which were treated easily with drug administrations.
Conclusions: InnoSEAL Plus is expected to be functionally not inferior to other conventional hemostatic agents. However, it is necessary to confirm this through multicenter prospective studies in the future.
Keywords : Pilot study; Hemostatics; Hepatectomy; Mussel adhesion

 

November 2021, 25 (4)
Full Text(PDF) Free
PubMed

Social Network Service
Services

Cited By Articles
  • CrossRef (0)